Literature DB >> 21170046

Detrimental effects of adenosine signaling in sickle cell disease.

Yujin Zhang1, Yingbo Dai, Jiaming Wen, Weiru Zhang, Almut Grenz, Hong Sun, Lijian Tao, Guangxiu Lu, Danny C Alexander, Michael V Milburn, Louvenia Carter-Dawson, Dorothy E Lewis, Wenzheng Zhang, Holger K Eltzschig, Rodney E Kellems, Michael R Blackburn, Harinder S Juneja, Yang Xia.   

Abstract

Hypoxia can act as an initial trigger to induce erythrocyte sickling and eventual end organ damage in sickle cell disease (SCD). Many factors and metabolites are altered in response to hypoxia and may contribute to the pathogenesis of the disease. Using metabolomic profiling, we found that the steady-state concentration of adenosine in the blood was elevated in a transgenic mouse model of SCD. Adenosine concentrations were similarly elevated in the blood of humans with SCD. Increased adenosine levels promoted sickling, hemolysis and damage to multiple tissues in SCD transgenic mice and promoted sickling of human erythrocytes. Using biochemical, genetic and pharmacological approaches, we showed that adenosine A(2B) receptor (A(2B)R)-mediated induction of 2,3-diphosphoglycerate, an erythrocyte-specific metabolite that decreases the oxygen binding affinity of hemoglobin, underlies the induction of erythrocyte sickling by excess adenosine both in cultured human red blood cells and in SCD transgenic mice. Thus, excessive adenosine signaling through the A(2B)R has a pathological role in SCD. These findings may provide new therapeutic possibilities for this disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21170046      PMCID: PMC4838392          DOI: 10.1038/nm.2280

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  43 in total

1.  Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).

Authors:  Belinda Chan; Diane Wara; John Bastian; Michael S Hershfield; John Bohnsack; Colleen G Azen; Robertson Parkman; Kenneth Weinberg; Donald B Kohn
Journal:  Clin Immunol       Date:  2005-08-22       Impact factor: 3.969

Review 2.  Functions, of 2,3-bisphosphoglycerate and its metabolism.

Authors:  H Chiba; R Sasaki
Journal:  Curr Top Cell Regul       Date:  1978

Review 3.  Sickle cell disease: no longer a single gene disorder.

Authors:  D H Chui; G J Dover
Journal:  Curr Opin Pediatr       Date:  2001-02       Impact factor: 2.856

4.  In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency.

Authors:  Denise A Carbonaro; Xiangyang Jin; Denise Petersen; Xingchao Wang; Fred Dorey; Ki Soo Kil; Melissa Aldrich; Michael R Blackburn; Rodney E Kellems; Donald B Kohn
Journal:  Mol Ther       Date:  2006-05-02       Impact factor: 11.454

Review 5.  [Advances in sickle cell disease].

Authors:  Mariane de Montalembert
Journal:  Bull Acad Natl Med       Date:  2008-10       Impact factor: 0.144

6.  Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling.

Authors:  Tiejuan Mi; Shahrzad Abbasi; Hong Zhang; Karen Uray; Janci L Chunn; Ling Wei Xia; Jose G Molina; Norman W Weisbrodt; Rodney E Kellems; Michael R Blackburn; Yang Xia
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

7.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.

Authors:  Arun Sreekumar; Laila M Poisson; Thekkelnaycke M Rajendiran; Amjad P Khan; Qi Cao; Jindan Yu; Bharathi Laxman; Rohit Mehra; Robert J Lonigro; Yong Li; Mukesh K Nyati; Aarif Ahsan; Shanker Kalyana-Sundaram; Bo Han; Xuhong Cao; Jaeman Byun; Gilbert S Omenn; Debashis Ghosh; Subramaniam Pennathur; Danny C Alexander; Alvin Berger; Jeffrey R Shuster; John T Wei; Sooryanarayana Varambally; Christopher Beecher; Arul M Chinnaiyan
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

8.  PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years.

Authors:  M S Hershfield
Journal:  Clin Immunol Immunopathol       Date:  1995-09

9.  Role and induction of 2,3-bisphosphoglycerate synthase.

Authors:  R Sasaki; H Chiba
Journal:  Mol Cell Biochem       Date:  1983       Impact factor: 3.396

10.  A network model to predict the risk of death in sickle cell disease.

Authors:  Paola Sebastiani; Vikki G Nolan; Clinton T Baldwin; Maria M Abad-Grau; Ling Wang; Adeboye H Adewoye; Lillian C McMahon; Lindsay A Farrer; James G Taylor; Gregory J Kato; Mark T Gladwin; Martin H Steinberg
Journal:  Blood       Date:  2007-06-28       Impact factor: 22.113

View more
  91 in total

Review 1.  Metabolomics as a key integrator for "omic" advancement of personalized medicine and future therapies.

Authors:  Andrea D Eckhart; Kirk Beebe; Mike Milburn
Journal:  Clin Transl Sci       Date:  2012-06       Impact factor: 4.689

2.  Adenosine receptor crossroads in sickle cell disease.

Authors:  Mark T Gladwin
Journal:  Nat Med       Date:  2011-01       Impact factor: 53.440

3.  Plasma metabolomic profiles enhance precision medicine for volunteers of normal health.

Authors:  Lining Guo; Michael V Milburn; John A Ryals; Shaun C Lonergan; Matthew W Mitchell; Jacob E Wulff; Danny C Alexander; Anne M Evans; Brandi Bridgewater; Luke Miller; Manuel L Gonzalez-Garay; C Thomas Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-17       Impact factor: 11.205

Review 4.  Ischemia and reperfusion--from mechanism to translation.

Authors:  Holger K Eltzschig; Tobias Eckle
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

5.  Early hemorrhage triggers metabolic responses that build up during prolonged shock.

Authors:  Angelo D'Alessandro; Hunter B Moore; Ernest E Moore; Matthew Wither; Travis Nemkov; Eduardo Gonzalez; Anne Slaughter; Miguel Fragoso; Kirk C Hansen; Christopher C Silliman; Anirban Banerjee
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-04-15       Impact factor: 3.619

Review 6.  Beneficial and detrimental role of adenosine signaling in diseases and therapy.

Authors:  Hong Liu; Yang Xia
Journal:  J Appl Physiol (1985)       Date:  2015-08-27

Review 7.  Sickle cell disease: renal manifestations and mechanisms.

Authors:  Karl A Nath; Robert P Hebbel
Journal:  Nat Rev Nephrol       Date:  2015-02-10       Impact factor: 28.314

Review 8.  The role of adenosine signaling in sickle cell therapeutics.

Authors:  Joshua J Field; David G Nathan; Joel Linden
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

9.  Elevated ecto-5'-nucleotidase-mediated increased renal adenosine signaling via A2B adenosine receptor contributes to chronic hypertension.

Authors:  Weiru Zhang; Yujin Zhang; Wei Wang; Yingbo Dai; Chen Ning; Renna Luo; Kaiqi Sun; Louise Glover; Almut Grenz; Hong Sun; Lijian Tao; Wenzheng Zhang; Sean P Colgan; Michael R Blackburn; Holger K Eltzschig; Rodney E Kellems; Yang Xia
Journal:  Circ Res       Date:  2013-04-12       Impact factor: 17.367

10.  Remote ischemic conditioning enhances oxygen supply to ischemic brain tissue in a mouse model of stroke: Role of elevated 2,3-biphosphoglycerate in erythrocytes.

Authors:  Lin Wang; Changhong Ren; Yang Li; Chen Gao; Ning Li; Haiyan Li; Di Wu; Xiaoduo He; Changqing Xia; Xunming Ji
Journal:  J Cereb Blood Flow Metab       Date:  2020-09-15       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.